PROMOTING ACCESS TO AFRICAN RESEARCH

Journal of Pharmacy & Bioresources

Log in or Register to get access to full text downloads.

Remember me or Register



DOWNLOAD FULL TEXT Open Access  DOWNLOAD FULL TEXT Subscription or Fee Access

Effect of fixed-dose sizes on in vitro properties of artemether-lumefantrine tablets

Olubukola A. Odeniran, Obiageri O. Obodozie-Ofoegbu, Jacinta N. Nwogu, Chinedum P. Babalola

Abstract


The World Health Organization recommends artemisinin combination therapy (ACT) for the treatment of uncomplicated malaria. Artemether-lumefantrine (A-L) is a fixed-dose combination (FDC) of two active antimalarial ingredients. Pharmaceutical equivalence (PE) of three FDC: Coartem® (20/120 mg); B (40/240 mg) and C (80/480 mg) were investigated. Assay was performed for A-L separately with a validated HPLC method. Assay for artemether in Coartem®, B and C were 93.34%, 98.27% and 100.78% while for lumefantrine 96.44 %, 97.34 % and 93.52 % respectively were obtained. From the dissolution test, the mean percent of artemether released after 1 h for Coartem®, B, and C were 38.67%, 32.86% and 50.74% respectively. Lumefantrine after 45mins gave 93.89%, 64.39% and 64.76% respectively. The data obtained were compared using ANOVA which was not statistically significant (P>0.05). The f2 values for B & C was greater than 50 suggesting their similarity with Coartem®. The focus of this study is to evaluate their in vitro properties and their overall performance.

Keywords: Artemether-lumefantrine tablets; Fixed-dose combination; Pharmaceutical equivalence; Antimalarial




AJOL African Journals Online